High-grade B-cell lymphoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Tarsheen Sethi, MD, MSCI
Yale University
New Haven, CT

Social-twitter-icon.png tarsheen2

Note: High-grade B-cell lymphoma (HGBL) was not considered as a named entity until the 2016 revision of the WHO guidelines, and includes entities such as double-hit lymphoma and triple-hit lymphoma which were previously classified under diffuse large B-cell lymphoma. We will populate this page with relevant regimens over time.

1 regimens on this page
1 variants on this page

Relapsed or refractory, subsequent lines of therapy

Loncastuximab tesirine monotherapy


FDA-recommended dose
Study Years of enrollment Evidence
Caimi et al. 2021 (LOTIS-2) 2018-2019 Phase 2 (RT)

Antibody-drug conjugate therapy

  • Loncastuximab tesirine (Zynlonta) as follows:
    • Cycles 1 & 2: 0.15 mg/kg IV over 30 minutes once on day 1
    • Cycle 3 onwards: 0.075 mg/kg IV over 30 minutes once on day 1

Supportive therapy

21-day cycles for up to 18 cycles (1 year)


  1. LOTIS-2: Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800. Epub 2021 May 11. link to original article contains dosing details in abstract PubMed NCT03589469